HCPCS Code J2353: Injection, Octreotide, 1 mg

## **HCPCS code J2353 documentation requirements** The documentation requirements for HCPCS Code J2353, which is for the injection of octreotide depot form (1 mg) intramuscularly, generally include the following key elements: - A documented diagnosis that supports the medical necessity of octreotide acetate or octreotide injection. Common approved indications include acromegaly, carcinoid tumor, VIPomas, gastroenteropancreatic neuroendocrine tumors, Cushing’s disease, pituitary gigantism, and other relevant endocrine or neuroendocrine conditions. - Documentation that the drug is prescribed by or in consultation with an endocrinologist or relevant specialist, especially for certain conditions like Cushing’s disease or acromegaly. - Evidence that the patient is an appropriate candidate for octreotide therapy, such as documentation that pituitary surgery is not possible or has not been curative for conditions like Cushing’s disease. - Prior authorization may be required, and documentation supporting medical necessity, such as patient history, clinical notes, and diagnostic test results, should be included. - Accurate recording of the doses/dosage and administration route (form for intramuscular injection, 1 mg) and related billing with appropriate administration codes. - If applicable, document any drug discard information using modifiers like JZ (zero substance discarded) or JG (drug acquired under 340B pricing program). - The medical record must demonstrate that any coverage criteria set by the payer, including Medicare Administrative Contractors (MACs), have been met. - Detailed provider notes should show moderate-level medical decision-making, including management of multiple diagnoses, treatment decisions, or medication management, which corresponds to the complexity level associated with this code.

## **J2353 billing requirements** The billing requirements for HCPCS Code J2353, which represents the injection of octreotide depot form for intramuscular injection (1 mg), include the following key points: - The drug should be billed under the category "Drugs, Administered by Injection" using HCPCS code J2353. - The service is associated with moderate-level medical decision-making and usually involves management of multiple diagnoses or prescription management. - Administration of the drug should be billed along with the appropriate drug administration CPT code. CPT code 96372 is a standard for administration. - Modifiers such as JZ or JG may be used if applicable to indicate drug discard or special pricing acquisition under United States government programs. - Documentation must support the medical necessity of the drug, including a valid diagnosis, treatment rationale, and administration details. - Providers should submit one unit of service with the appropriate dosage (1 mg per unit) without quantity-billing the drug multiple times for a single administration. - Prior authorization is often required by payers before billing. - Detailed medical record documentation supporting the moderate complexity of the encounter is necessary. - Providers must ensure compliance with payer-specific rules, local coverage determinations, and CMS claims processing guidelines for drug billing. Medicare and other payers vary reimbursement rates for J2353, with average Medicare reimbursement around $228 per unit in 2025. Providers should check individual contracts and payers for precise rates.

## **Other relevant codes** Other relevant HCPCS codes related to HCPCS J2353 (injection, octreotide, depot form for intramuscular injection, 1 mg) include: - **J2354**: Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg. This is used for the immediate-release form of octreotide rather than the long-acting depot form. - **J2502**: Injection, pasireotide long acting, 1 mg, another somatostatin analog used in similar endocrine conditions. - **J1930** and **J1932**: Injection, lanreotide (1 mg), another related hormonal therapy used for neuroendocrine tumors and acromegaly treatment.